Dr. Kuralay Atageldiyeva specialist in Internal Medicine and Endocrinology, obtained her MD and Internship in Internal Medicine from Kazakh National Medical University named by S.D.Asfendiyarov, Almaty, Kazakhstan. She had clinical residency in Endocrinology in Scientific Research Institute of Cardiology and Internal Diseases, Almaty.  She has completed doctorate course at the graduate school of Asahikawa Medical University (Japan) and was conferred Ph.D in Medicine in 2016.
Before joining Nazarbayev University in 2017, Dr.Atageldiyeva served as physician, endocrinologist and Head of Research management department of Scientific Research Institute of Cardiology and Internal Diseases in different periods of time.

Research Interests
1.    Diabetic nephropathy. Alterations in mesangial cells, proximal tubular cells evoked by high glucose, changes in cell signaling, dysregulation of gene expression and cellular functions;
2.    Effects of a Low carbohydrate diet on insulin sensitivity, fat accumulation, and gluconeogenesis in the kidney and the liver. Obesity is highly associated with risks of type 2 diabetes, hypertension, hyperlipidemia, and cardiovascular disease. It is widely appreciated that diet is a key approach in maintaining adequate body weight especially for obese people with complications. Total calorie restriction is one common approach to dieting, with another being a nutrition-oriented restriction such as a low-carbohydrate diet or a low-fat diet. A  LCHD leads to less glucose influx to the portal vein from the gut, suppresses postprandial elevation of glucose, possibly resulting in amelioration of obesity and insulin resistance.
3.    Metabolic outcomes of a new glucose lowering agent Sodium-glucose cotransporter type 2 inhibitors in animal models of obesity and diabetes, and in healthy, obese and diabetic human subjects.

1.     K. Atageldiyeva, Y. Fujita , T. Yanagimachi, K.Mizumoto, Y.Takeda, J. Honjo, Y. Takiyama, A.Abiko, Y.Makino, M.Haneda., Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice, Plos One, June 21, 2016, http://dx.doi.org/10.1371/journal.pone.0157672
2.    Yanagimachi T, Fujita Y, Takeda Y, Honjo J, Atageldiyeva KK, Takiyama Y, Abiko A, Makino Y, Kieffer TJ, Haneda M.    Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1-30) expression is upregulated in diabetes and PEGylated GIP(1-30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice, Diabetologia. 2016 Mar; 59(3):533-41. doi: 10.1007/s00125-015-3842-y.
3.     H.Kitsunai, Y.Makino, H.Sakagami, K.Mizumoto, T.Yanagimachi, K.Atageldiyeva, Y.Takeda, Y.Fujita, A.Abiko, Y.Takiyama, M.Haneda,  High glucose induces platelet‐derived growth factor‐C via carbohydrate response element‐binding protein in glomerular mesangial cells, Physiological Reports, Published 31 March 2016 Vol. 4 no. e12730 DOI: 10.14814/phy2.12730
4.    Y Makino, KK Atageldiyeva, H Kitsunai, K Mizumoto, T Yanagimachi, Y Fujita, A Abiko, Y Takiyama, M Haneda, High glucose induces membrane-bound transcription factor peptidase site1 via carbohydrate response element binding protein to modulate ER stress in mesangial cells, Diabetologia, Vol. 58. 233 SPRING ST, NEW YORK, NY 10013 USA: SPRINGER, 2015.
5.     Y.Takiyama, M.Maeda, K. Atageldiyeva, T.Yanagimachi, J.Honjo, Y.Fujita, A.Abiko, M.Haneda, A New Player in Diabetic Nephropathy: Metallothionein 3 Is a Target for Hypoxia Inducible Factor-1, DIABETES. Vol. 64. 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA: AMER DIABETES ASSOC, 2015.
6.     Y Takiyama, M Maeda, KK Atageldiyeva, T Yanagimachi, J Honjo, Y Fujita, Y Makino, M Haneda    Zinc exerts anti-fibrotic action by inhibiting TGF-beta1-induced type I collagen and fibronectin in human renal proximal tubular cells, DIABETOLOGIA. Vol. 57. 233 SPRING ST, NEW YORK, NY 10013 USA: SPRINGER, 2014.
7.     Y.Takiyama, R. Bessho, M.Maeda, KK Atageldiyeva, T. Yanagimachi, J. Honjo, Y. Fujita, Y.Makino, M.Haneda, SGLT2 Inhibitor Luseogliflozin (TS-071) Protects from Diabetic Nephropathy in an Animal Model of Type 2 Diabetes, DIABETES. Vol. 63. 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA: AMER DIABETES ASSOC, 2014.
8.     KK Atageldiyeva, Y Fujita, T Yanagimachi, J Honjo, A Abiko, Y Takiyama, Y Makino, M Haneda,     Low carbohydrate diet and SGLT-2 inhibitors dissimilarly influenced on body weight and adiposity in normal mice, DIABETOLOGIA. Vol. 58. 233 SPRING ST, NEW YORK, NY 10013 USA: SPRINGER, 2015.